Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose escalation study of intravenous IQNLF in healthy volunteers
NL-OMON36585Phase 1Active, not recruiting
- Sponsor
- IQ Therapeutics
- Start
- Feb 2011
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anthrax, sponsored by IQ Therapeutics. Primary endpoint: Safety and tolerability. Started Feb 2011; status: active, not recruiting.
02
Conditions
anthrax
Beyond the preview
Go deeper on NL-OMON36585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36585.